Literature DB >> 30357539

Characteristics and Prognosis of Primary Head and Neck Angiosarcomas: A Surveillance, Epidemiology, and End Results Program (SEER) Analysis of 1250 Cases.

Kevin C Lee1, Sung-Kiang Chuang2,3, Elizabeth M Philipone4, Scott M Peters5.   

Abstract

Head and neck angiosarcomas (HN-AS) are rare malignancies with a poor prognosis relative to other soft tissue sarcomas. To date, the HN-AS literature has been limited to short reports and single-institution experiences. This study evaluated patients registered with the Surveillance, Epidemiology, and End Results (SEER) program who had been diagnosed with a primary HN-AS. Predictors were drawn from demographic and baseline tumor characteristics. Outcomes were survival months and cause of death. Kaplan-Meier analyses were used to estimate overall (OS) and disease-specific survival (DSS) rates. Cox proportional hazards regression models were used for multivariate analyses. A total of 1250 patients (mean age 73.3 years) were identified, and nearly all lesions (93.5%) were cutaneous. Two- and 5-year OS rates were 47.3% (95% CI 44.3-50.3) and 26.5% (95% CI 23.7-29.3), while 2- and 5-year DSS rates were 66.6% (95% CI 63.6-69.6) and 48.3% (95% CI 44.5-52.1). In the univariate analyses, age, race, tumor grade, tumor size, AJCC stage, SEER historic stage, and surgery were significant predictors of both OS and DSS. Multivariate regression revealed that independent predictors of poor OS and DSS were older age [OS: HR 1.04 (95% CI 1.02-1.05), p < 0.01; DSS: HR 1.03 (95% CI 1.01-1.05), p < 0.01], increased tumor size [OS: HR 1.01 (95% CI 1.01-1.01), p < 0.01; DSS: HR 1.01 (95% CI 1.01-1.02), p < 0.01], and distant disease [OS: HR 2.97 (95% CI 1.65-5.34), p < 0.01; DSS: HR 4.99 (95% CI 2.50-9.98), p < 0.01]. Age, tumor size, and disease extent were determinants of HN-AS survival. When all other factors were controlled, lower histologic grade and surgery did not improve the risk of death.

Entities:  

Keywords:  Angiosarcoma; Head and neck malignancy; Population data; Survival analysis

Mesh:

Year:  2018        PMID: 30357539      PMCID: PMC6684669          DOI: 10.1007/s12105-018-0978-3

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  24 in total

1.  Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma.

Authors:  J Huang; W J Mackillop
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

2.  Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

Authors:  Nicolas Penel; Binh Nguyen Bui; Jacques-Olivier Bay; Didier Cupissol; Isabelle Ray-Coquard; Sophie Piperno-Neumann; Pierre Kerbrat; Charles Fournier; Sophie Taieb; Marta Jimenez; Nicolas Isambert; Frédéric Peyrade; Christine Chevreau; Emmanuelle Bompas; Etienne G C Brain; Jean-Yves Blay
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

3.  Treatment and prognosis of angiosarcoma of the scalp and face: a retrospective analysis of 48 patients.

Authors:  K Ogawa; K Takahashi; Y Asato; Y Yamamoto; K Taira; S Matori; S Iraha; N Yagi; A Yogi; S Haranaga; J Fujita; H Uezato; S Murayama
Journal:  Br J Radiol       Date:  2012-07-17       Impact factor: 3.039

4.  Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007.

Authors:  Jorge Albores-Saavedra; Arnold M Schwartz; Donald E Henson; Lara Kostun; Alexandra Hart; David Angeles-Albores; Fredy Chablé-Montero
Journal:  Ann Diagn Pathol       Date:  2010-12-28       Impact factor: 2.090

Review 5.  Stewart-Treves syndrome: pathogenesis and management.

Authors:  Amit Sharma; Robert A Schwartz
Journal:  J Am Acad Dermatol       Date:  2012-06-08       Impact factor: 11.527

6.  Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp.

Authors:  B Ashleigh Guadagnolo; Gunar K Zagars; Dejka Araujo; Vinod Ravi; Thomas D Shellenberger; Erich M Sturgis
Journal:  Head Neck       Date:  2010-10-19       Impact factor: 3.147

7.  Surgical treatment of angiosarcoma of the scalp: less is more.

Authors:  Alexandra Buschmann; Marcus Lehnhardt; Nidal Toman; Peter Preiler; M Sedigh Salakdeh; Thomas Muehlberger
Journal:  Ann Plast Surg       Date:  2008-10       Impact factor: 1.539

8.  Sporadic cutaneous angiosarcomas: a proposal for risk stratification based on 69 cases.

Authors:  Andrea T Deyrup; Jesse K McKenney; Mourad Tighiouart; Andrew L Folpe; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2008-01       Impact factor: 6.394

9.  An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.

Authors:  M Agulnik; J L Yarber; S H Okuno; M von Mehren; B D Jovanovic; B E Brockstein; A M Evens; R S Benjamin
Journal:  Ann Oncol       Date:  2012-08-21       Impact factor: 32.976

10.  Cutaneous soft tissue sarcoma incidence patterns in the U.S. : an analysis of 12,114 cases.

Authors:  Panta Rouhani; Christopher D M Fletcher; Susan S Devesa; Jorge R Toro
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

View more
  20 in total

1.  Histologic and Immunopathologic Variability in Primary Intraoral Angiosarcoma: A Case Report and Review of the Literature.

Authors:  Massimo Di Battista; Mark R Darling; Edgar Scrivener; Richard Stapleford; Bret Wehrli; Christina McCord
Journal:  Head Neck Pathol       Date:  2020-02-05

Review 2.  Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis.

Authors:  Isidro Machado; Francisco Giner; Javier Lavernia; Julia Cruz; Víctor Traves; Celia Requena; Beatriz Llombart; José Antonio López-Guerrero; Antonio Llombart-Bosch
Journal:  Histol Histopathol       Date:  2020-09-04       Impact factor: 2.303

Review 3.  Management of Cutaneous Angiosarcoma: an Update Review.

Authors:  Siwei Bi; Ai Zhong; Xiya Yin; Jingyi Li; Ying Cen; Junjie Chen
Journal:  Curr Treat Options Oncol       Date:  2022-02-19

4.  Prognostic Relevance of Pretreatment Peripheral Neutrophil Count and Neutrophil-to-lymphocyte Ratio in Primary Cutaneous Angiosarcoma.

Authors:  Kentaro Awaji; Takuya Miyagawa; Jun Omatsu; Hiroko Numajiri; Toru Kawai; Kaoru Funamizu; Ryosuke Saigusa; Daisuke Yamada; Yoshihide Asano; Shinichi Sato
Journal:  Acta Derm Venereol       Date:  2021-08-25       Impact factor: 3.875

5.  Imaging findings of cutaneous angiosarcoma of the scalp: Comparison with cutaneous squamous cell carcinoma.

Authors:  Masaya Kawaguchi; Hiroki Kato; Natsuko Suzui; Tatsuhiko Miyazaki; Hiroyuki Tomita; Akira Hara; Kanako Matsuyama; Mariko Seishima; Masayuki Matsuo
Journal:  Neuroradiol J       Date:  2021-03-03

6.  Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas.

Authors:  Marije E Weidema; Uta E Flucke; Winette T A van der Graaf; Vincent K Y Ho; Melissa H S Hillebrandt-Roeffen; Yvonne M H Versleijen-Jonkers; Olga Husson; Ingrid M E Desar
Journal:  Cancers (Basel)       Date:  2019-11-12       Impact factor: 6.639

Review 7.  Optimal Clinical Management and the Molecular Biology of Angiosarcomas.

Authors:  Tom Wei-Wu Chen; Jessica Burns; Robin L Jones; Paul H Huang
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

8.  Clinical implications of systemic and local immune responses in human angiosarcoma.

Authors:  Jason Yongsheng Chan; Grace Fangmin Tan; Joe Yeong; Chee Wee Ong; Dave Yong Xiang Ng; Elizabeth Lee; Joanna Koh; Cedric Chuan-Young Ng; Jing Yi Lee; Wei Liu; Ru Xin Wong; Chin-Ann Johnny Ong; Mohamad Farid; Bin Tean Teh; Khee Chee Soo
Journal:  NPJ Precis Oncol       Date:  2021-02-12

9.  Primary angiosarcoma of the oral cavity in a young adult.

Authors:  Bhagat Singh Lali; Zachariah Chowdhury; Monika Gupta; Aseem Mishra
Journal:  Autops Case Rep       Date:  2020-12-08

10.  Individual multi-catheter mould technique in high-dose-rate brachytherapy - personalized approach in treating multifocal angiosarcoma of the face.

Authors:  Marta Szlag; Piotr Wojcieszek; Sylwia Kellas-Ślęczka; Kamil Krysiak; Agnieszka Cholewka; Małgorzata Stąpór-Fudzińska; Tomasz Krzysztofiak; Marek Fijałkowski
Journal:  J Contemp Brachytherapy       Date:  2019-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.